“…Favorable results with combined modality treatment have been achieved for patients with benign disease (DPAM) and complete cytoreduction, with 5-and 10-year survival rates of approximately 75%-100% and 68%, respectively [9,10,41]. However, patients with malignant disease (PMCA) or intermediate disease (PMCA-I) showed a significantly worse prognosis, with 5-and 10-year survival rates, respectively, of 50% and 21% for PMCA-I and 14% and 3% for PMCA [9].…”